Market Overview

UPDATE: CRT Capital Upgrades Akorn


CRT Capital upgraded Akorn, Inc. (NASDAQ: AKRX) from Fair Value to Buy with a $46 price target.

Analyst Tim Chiang believed “the recent sell off in AKRX shares post 3Q results creates a potential buying opportunity, based on our view that the Company will benefit from solid pricing trends in products like topical Clobetasol propionate (a commonly prescribed corticosteroid for the treatment of various skin conditions like eczema).”

Chiang estimated 2014 to 2016 “Clobetasol sales of $39M, $85M, and $102M, respectively. Our analysis of this suggest that recent price hikes by a competitor, Taro, could lead to higher sales and profits for all of the major players in this market, with Akorn currently the No.2 player by market share. We forecast Clobetasol’s gross margins above 90 percent throughout the F’14 – F’20 period.”

“Clobetasol represents a large market, counting over 6 million retail prescriptions in the US in 2013. The majority of those, about 84 percent of the prescription count (and likely 50 percent of the total amount spent) are for the cream, ointment and topical solution presentations,” according to the analyst report.

Chiang concluded that “AKRX shares trade at ~22x our 15 EPS forecast of $1.68, a ~30 percent premium to its peer group. While AKRX shares do trade at a premium, we believe Akorn has a 14-18 CAGR of ~30 percent, which is higher than its peers.”

Akorn recently traded at $38.33, up 1.73 percent.

Latest Ratings for AKRX

Mar 2019Initiates Coverage OnHold
Oct 2018UpgradesNeutralOverweight
Apr 2017DowngradesOverweightNeutral

View More Analyst Ratings for AKRX
View the Latest Analyst Ratings

Posted-In: CRT Tim ChiangAnalyst Color Upgrades Price Target Analyst Ratings


Related Articles (AKRX)

View Comments and Join the Discussion!

Midday Losers From November 14: Movado Group, Vascular Solutions, SFX, Hertz, Sina

iPhone 6 Vs. Entire Galaxy Line: Will Apple Win The Holidays?